当前位置: 首页 >> 检索结果
481. Radiofrequency Versus Cryoballoon Catheter Ablation for Paroxysmal Atrial Fibrillation: Durability of Pulmonary Vein Isolation and Effect on Atrial Fibrillation Burden: The RACE-AF Randomized Controlled Trial.
作者: Samuel K Sørensen.;Arne Johannessen.;René Worck.;Morten L Hansen.;Jim Hansen.
来源: Circ Arrhythm Electrophysiol. 2021年14卷5期e009573页
[Figure: see text].
482. International Evidence Based Reappraisal of Genes Associated With Arrhythmogenic Right Ventricular Cardiomyopathy Using the Clinical Genome Resource Framework.
作者: Cynthia A James.;Jan D H Jongbloed.;Ray E Hershberger.;Ana Morales.;Daniel P Judge.;Petros Syrris.;Kalliopi Pilichou.;Argelia Medeiros Domingo.;Brittney Murray.;Julia Cadrin-Tourigny.;Ronald Lekanne Deprez.;Rudy Celeghin.;Alexandros Protonotarios.;Babken Asatryan.;Emily Brown.;Elizabeth Jordan.;Jennifer McGlaughon.;Courtney Thaxton.;C Lisa Kurtz.;J Peter van Tintelen.
来源: Circ Genom Precis Med. 2021年14卷3期e003273页
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited disease characterized by ventricular arrhythmias and progressive ventricular dysfunction. Genetic testing is recommended, and a pathogenic variant in an ARVC-associated gene is a major criterion for diagnosis according to the 2010 Task Force Criteria. As incorrect attribution of a gene to ARVC can contribute to misdiagnosis, we assembled an international multidisciplinary ARVC Clinical Genome Resource Gene Curation Expert Panel to reappraise all reported ARVC genes.
483. Randomized Clinical Comparison of the Dual-Therapy CD34 Antibody-Covered Sirolimus-Eluting Combo Stent With the Sirolimus-Eluting Orsiro Stent in Patients Treated With Percutaneous Coronary Intervention: The SORT OUT X Trial.
作者: Lars Jakobsen.;Evald H Christiansen.;Phillip Freeman.;Johnny Kahlert.;Karsten Veien.;Michael Maeng.;Bent Raungaard.;Julia Ellert.;Anton B Villadsen.;Steen D Kristensen.;Ole Ahlehoff.;Martin K Christensen.;Christian J Terkelsen.;Hans Erik Bøtker.;Jens Aaroe.;Troels Thim.;Leif Thuesen.;Ahmed Aziz.;Ashkan Eftekhari.;Rebekka V Jensen.;Nicolaj B Støttrup.;Jeppe G Rasmussen.;Anders Junker.;Svend E Jensen.;Henrik S Hansen.;Lisette O Jensen.
来源: Circulation. 2021年143卷22期2155-2165页
Target lesion failure remains an issue with contemporary drug-eluting stents. Thus, the dual-therapy sirolimus-eluting and CD34+ antibody-coated Combo stent (DTS) was designed to further improve early healing. This study aimed to investigate whether the DTS is noninferior to the sirolimus-eluting Orsiro stent (SES) in an all-comers patient population.
484. Novel Supreme Drug-Eluting Stents With Early Synchronized Antiproliferative Drug Delivery to Inhibit Smooth Muscle Cell Proliferation After Drug-Eluting Stents Implantation in Coronary Artery Disease: Results of the PIONEER III Randomized Clinical Trial.
作者: Alexandra J Lansky.;Dean J Kereiakes.;Andreas Baumbach.;Stephan Windecker.;Yasin Hussain.;Cody Pietras.;Ovidiu Dressler.;Ozgu Issever.;Michael Curtis.;Barry Bertolet.;James P Zidar.;Pieter C Smits.;Victor Alfonso Jiménez Díaz.;Brent McLaurin.;Sjoerd Hofma.;Ángel Cequier.;Nabil Dib.;Edouard Benit.;Anthony Mathur.;David Brogno.;Jacques Berland.;Joanna Wykrzykowska.;Guy Piegari.;Salvatore Brugaletta.;Shigeru Saito.;Martin B Leon.; .
来源: Circulation. 2021年143卷22期2143-2154页
Accelerated endothelial healing after targeted antiproliferative drug delivery may limit the long-term inflammatory response of drug-eluting stents (DESs). The novel Supreme DES is designed to synchronize early drug delivery within 4 to 6 weeks of implantation, leaving behind a prohealing permanent base layer. Whether the Supreme DES is safe and effective in the short term and can improve long-term clinical outcomes is not known.
485. Benefits and Harms of Hypertension and High-Normal Labels: A Randomized Experiment.
作者: Danielle Marie Muscat.;Georgina May Morris.;Katy Bell.;Erin Cvejic.;Jenna Smith.;Jesse Jansen.;Rae Thomas.;Carissa Bonner.;Jenny Doust.;Kirsten McCaffery.
来源: Circ Cardiovasc Qual Outcomes. 2021年14卷4期e007160页
Recent US guidelines lowered the threshold for diagnosing hypertension while other international guidelines use alternative/no labels for the same group (blood pressure [BP], <140/90 mm Hg). We investigated potential benefits and harms of hypertension and high-normal BP labels, compared with control, among people at lower risk of cardiovascular disease.
486. Prognostic Role of Prior Heart Failure Hospitalization Among Patients Hospitalized for Worsening Chronic Heart Failure.
作者: Vanessa Blumer.;Robert J Mentz.;Jie-Lena Sun.;Javed Butler.;Marco Metra.;Adriaan A Voors.;Adrian F Hernandez.;Christopher M O'Connor.;Stephen J Greene.
来源: Circ Heart Fail. 2021年14卷4期e007871页
Hospitalization for heart failure (HF) is associated with increased risk of death among patients with chronic HF. The degree to which hospitalization for HF is a distinct biologic entity with independent prognostic value versus a marker of higher risk chronic HF patients is unclear.
487. One-Year Outcomes of a Randomized Trial Comparing a Self-Expanding With a Balloon-Expandable Transcatheter Aortic Valve.
作者: Won-Keun Kim.;Thomas Walther.;Christof Burgdorf.;Helge Möllmann.;Axel Linke.;Simon Redwood.;Christian Thilo.;Michael Hilker.;Michael Joner.;Holger Thiele.;Lars Conzelmann.;Lenard Conradi.;Sebastian Kerber.;Gerhard Schymik.;Bernard Prendergast.;Oliver Husser.;Johannes Blumenstein.;Stefan Stortecky.;Dik Heg.;Arnaud Künzi.;Peter Jüni.;Stephan Windecker.;Thomas Pilgrim.;Jonas Lanz.; .
来源: Circulation. 2021年143卷12期1267-1269页 488. Treatment Effects of Interleukin-6 Receptor Antibodies for Modulating the Systemic Inflammatory Response After Out-of-Hospital Cardiac Arrest (The IMICA Trial): A Double-Blinded, Placebo-Controlled, Single-Center, Randomized, Clinical Trial.
作者: Martin Abild Stengaard Meyer.;Sebastian Wiberg.;Johannes Grand.;Anna Sina Pettersson Meyer.;Laust Emil Roelsgaard Obling.;Martin Frydland.;Jakob Hartvig Thomsen.;Jakob Josiassen.;Jacob Eifer Møller.;Jesper Kjaergaard.;Christian Hassager.
来源: Circulation. 2021年143卷19期1841-1851页
Patients experiencing out-of-hospital cardiac arrest who remain comatose after initial resuscitation are at high risk of morbidity and mortality attributable to the ensuing post-cardiac arrest syndrome. Systemic inflammation constitutes a major component of post-cardiac arrest syndrome, and IL-6 (interleukin-6) levels are associated with post-cardiac arrest syndrome severity. The IL-6 receptor antagonist tocilizumab could potentially dampen inflammation in post-cardiac arrest syndrome. The objective of the present trial was to determine the efficacy of tocilizumab to reduce systemic inflammation after out-of-hospital cardiac arrest of a presumed cardiac cause and thereby potentially mitigate organ injury.
489. Implications of Atrial Fibrillation on the Mechanisms of Mitral Regurgitation and Response to MitraClip in the COAPT Trial.
作者: Zachary M Gertz.;Howard C Herrmann.;D Scott Lim.;Saibal Kar.;Samir R Kapadia.;Grant W Reed.;Rishi Puri.;Amar Krishnaswamy.;Bernard J Gersh.;Neil J Weissman.;Federico M Asch.;Paul A Grayburn.;Ioanna Kosmidou.;Björn Redfors.;Zixuan Zhang.;William T Abraham.;JoAnn Lindenfeld.;Gregg W Stone.;Michael J Mack.
来源: Circ Cardiovasc Interv. 2021年14卷4期e010300页
Atrial fibrillation (AF), mitral regurgitation (MR), and left ventricular (LV) ejection fraction have a complex interplay. We evaluated the role of AF in patients with heart failure and moderate-to-severe or severe secondary MR enrolled in the randomized COAPT trial (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation) and its impact on mechanisms and outcomes with the MitraClip.
490. Optical Coherence Tomography Versus Intravascular Ultrasound and Angiography to Guide Percutaneous Coronary Interventions: The iSIGHT Randomized Trial.
作者: Daniel Chamié.;J Ribamar Costa.;Lucas P Damiani.;Dimytri Siqueira.;Sérgio Braga.;Ricardo Costa.;Henry Seligman.;Freddy Brito.;Guilherme Barreto.;Rodolfo Staico.;Fausto Feres.;Ricardo Petraco.;Alexandre Abizaid.
来源: Circ Cardiovasc Interv. 2021年14卷3期e009452页
[Figure: see text].
491. Hemodynamic Effects of Sacubitril-Valsartan Versus Enalapril in Patients With Heart Failure in the EVALUATE-HF Study: Effect Modification by Left Ventricular Ejection Fraction and Sex.
作者: Gary F Mitchell.;Scott D Solomon.;Amil M Shah.;Brian L Claggett.;James C Fang.;Joseph Izzo.;Cheryl A Abbas.;Akshay S Desai.; .
来源: Circ Heart Fail. 2021年14卷3期e007891页
Treatment with sacubitril-valsartan reduces mortality and heart failure (HF) events in HF with reduced ejection fraction and may reduce HF hospitalization in women with HF with preserved ejection fraction.
492. Effect of Empagliflozin as an Add-On Therapy on Decongestion and Renal Function in Patients With Diabetes Hospitalized for Acute Decompensated Heart Failure: A Prospective Randomized Controlled Study.
作者: Shunsuke Tamaki.;Takahisa Yamada.;Tetsuya Watanabe.;Takashi Morita.;Yoshio Furukawa.;Masato Kawasaki.;Atsushi Kikuchi.;Tsutomu Kawai.;Masahiro Seo.;Makoto Abe.;Jun Nakamura.;Kyoko Yamamoto.;Kiyomi Kayama.;Masatsugu Kawahira.;Kazuya Tanabe.;Kei Fujikawa.;Masahisa Hata.;Yohei Fujita.;Yutaka Umayahara.;Satsuki Taniuchi.;Shoji Sanada.;Ayumi Shintani.;Masatake Fukunami.
来源: Circ Heart Fail. 2021年14卷3期e007048页
Empagliflozin reduces the risk of hospitalization for heart failure in patients with type 2 diabetes and cardiovascular disease. We sought to elucidate the effect of empagliflozin as an add-on therapy on decongestion and renal function in patients with type 2 diabetes admitted for acute decompensated heart failure.
493. Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Left Ventricular Hypertrophy: Insights From the ARISTOTLE Trial.
作者: Sana M Al-Khatib.;Hillary Mulder.;Daniel Wojdyla.;Renato D Lopes.;Lars Wallentin.;John H Alexander.;Ziad Hijazi.;Shinya Goto.;Christopher B Granger.
来源: Circ Arrhythm Electrophysiol. 2021年14卷3期e009614页 494. Effects of a 2-Year Primary Care Lifestyle Intervention on Cardiometabolic Risk Factors: A Cluster-Randomized Trial.
作者: Christoph Höchsmann.;James L Dorling.;Corby K Martin.;Robert L Newton.;John W Apolzan.;Candice A Myers.;Kara D Denstel.;Emily F Mire.;William D Johnson.;Dachuan Zhang.;Connie L Arnold.;Terry C Davis.;Vivian Fonseca.;Carl J Lavie.;Eboni G Price-Haywood.;Peter T Katzmarzyk.; .
来源: Circulation. 2021年143卷12期1202-1214页
Intensive lifestyle interventions (ILIs) are the first-line approach to effectively treat obesity and manage associated cardiometabolic risk factors. Because few people have access to ILIs in academic health centers, primary care must implement similar approaches for a meaningful effect on obesity and cardiometabolic disease prevalence. To date, however, effective lifestyle-based obesity treatment in primary care is limited. We examined the effectiveness of a pragmatic ILI for weight loss delivered in primary care among a racially diverse, low-income population with obesity for improving cardiometabolic risk factors over 24 months.
495. Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure: Results From the EMBRACE-HF Trial.
作者: Michael E Nassif.;Mohammed Qintar.;Sheryl L Windsor.;Rita Jermyn.;David M Shavelle.;Fengming Tang.;Sumant Lamba.;Kunjan Bhatt.;John Brush.;Andrew Civitello.;Robert Gordon.;Orvar Jonsson.;Brent Lampert.;Jamie Pelzel.;Mikhail N Kosiborod.
来源: Circulation. 2021年143卷17期1673-1686页
Sodium glucose cotransporter 2 inhibitors (SGLT2 inhibitors) prevent heart failure (HF) hospitalizations in patients with type 2 diabetes and improve outcomes in those with HF and reduced ejection fraction, regardless of type 2 diabetes. Mechanisms of HF benefits remain unclear, and the effects of SGLT2 inhibitor on hemodynamics (filling pressures) are not known. The EMBRACE-HF trial (Empagliflozin Evaluation by Measuring Impact on Hemodynamics in Patients With Heart Failure) was designed to address this knowledge gap.
496. Patient Selection and Clinical Outcomes in the STOPDAPT-2 Trial: An All-Comer Single-Center Registry During the Enrollment Period of the STOPDAPT-2 Randomized Controlled Trial.
作者: Kenji Kanenawa.;Kyohei Yamaji.;Hiroaki Tashiro.;Takenori Domei.;Kenji Ando.;Hirotoshi Watanabe.;Takeshi Kimura.
来源: Circ Cardiovasc Interv. 2021年14卷2期e010007页
We sought to evaluate the impact of patient selection for the STOPDAPT-2 trial (Short and Optimal Duration of Dual Antiplatelet Therapy After Everolimus-Eluting Cobalt-Chromium Stent-2) on clinical outcomes in a registry from a single center that participated in the STOPDAPT-2 trial.
497. Efficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in the PIONEER-HF Trial.
作者: David D Berg.;Marc D Samsky.;Eric J Velazquez.;Carol I Duffy.;Yared Gurmu.;Eugene Braunwald.;David A Morrow.;Adam D DeVore.
来源: Circ Heart Fail. 2021年14卷2期e007034页
In patients stabilized during hospitalization for acute decompensated heart failure (HF), initiation of sacubitril/valsartan compared with enalapril decreased the risk of cardiovascular death or rehospitalization for HF without increasing the risk of adverse events. It is unknown whether potentially high-risk subpopulations have a similar risk-benefit profile.
498. Automated E-Counseling for Chronic Heart Failure: CHF-CePPORT Trial.
作者: Robert P Nolan.;Heather J Ross.;Michael E Farkouh.;Ella Huszti.;Sammy Chan.;Mustafa Toma.;Bianca D'Antono.;Michel White.;Scott Thomas.;Susan I Barr.;Sylvie Perreault.;Michael McDonald.;Shelley Zieroth.;Debra Isaac.;Andreas Wielgosz.;Lisa Marie Mielniczuk.
来源: Circ Heart Fail. 2021年14卷1期e007073页
International task force statements advocate telehealth programs to promote health-related quality of life for patients with chronic heart failure (CHF). To that end, we evaluated the efficacy and usability of an automated e-counseling program.
499. Higher Acceleration/Ejection Time Ratio Predicts Impaired Outcome in Aortic Valve Stenosis.
作者: Eigir Einarsen.;Dana Cramariuc.;Edda Bahlmann.;Helga Midtbo.;John B Chambers.;Eva Gerdts.
来源: Circ Cardiovasc Imaging. 2021年14卷1期e011467页
Acceleration time (AT)/ejection time (ET) ratio is a marker of aortic valve stenosis (AS) severity and predicts outcome in moderate-severe AS.
500. Time Delay, Infarct Size, and Microvascular Obstruction After Primary Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial Infarction.
作者: Björn Redfors.;Reza Mohebi.;Gennaro Giustino.;Shmuel Chen.;Harry P Selker.;Holger Thiele.;Manesh R Patel.;James E Udelson.;E Magnus Ohman.;Ingo Eitel.;Christopher B Granger.;Akiko Maehara.;Ziad A Ali.;Ori Ben-Yehuda.;Gregg W Stone.
来源: Circ Cardiovasc Interv. 2021年14卷2期e009879页
Symptom-to-balloon time (SBT) and door-to-balloon time (DBT) are both considered important metrics in patients undergoing primary percutaneous coronary intervention (pPCI) for ST-segment-elevation myocardial infarction (STEMI). We sought to assess the relationship of SBT and DBT with infarct size and microvascular obstruction (MVO) after pPCI.
|